Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dexcom (DXCM)
NASDAQ:DXCM
Dexcom (DXCM) Stock Price & Analysis
3,079 Followers
DXCM Stock Chart & Stats
Day’s Range$132.47 - $138.5
52-Week Range― - ―
Previous Close$134
Volume3.24M
Average Volume (3M)N/A
Market Cap
$51.66B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
Apr 25, 2024EPS Estimate
$0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$154.29Price Target Upside11.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Dexcom News
Bulls Say, Bears Say
Bulls Say
Legal MilestoneFavorable Court Ruling for Dexcom with a U.S. District Court of Delaware patent jury decision indicating no infringement, which supports a positive outlook for the company's intellectual property and market position.
Market Expansion StrategyWith Stelo's over-the-counter availability, Dexcom is poised to tap into a significant patient pool, bolstered by competitive pricing, direct-to-consumer marketing, and efforts to build payer coverage.
Product Approval And Market PotentialFDA approval of Stelo, Dexcom's 15-day sensor for type 2 non-insulin users, now cleared for over-the-counter sales, potentially opening up a new total addressable market that's not yet reflected in the current stock price.
Bears Say
Legal IssuesDexcom faced a negative outcome in a patent dispute, voted 'Yes' for infringing the patent related to inserter technology.
Market PenetrationRoche’s CGM system's delayed launch outside the US and lack of details on the US release could hinder its market penetration.
Product PerformanceRoche's Accu-Check SmartGuide CGM has a higher MARD compared to competitors, which might reduce its competitive advantage.
---
Ownership Overview
2.91% Insiders
36.31% Mutual Funds
25.59% Other Institutional Investors
35.19% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DXCM FAQ
What was Dexcom’s price range in the past 12 months?
Currently, no data Available
What is Dexcom’s market cap?
Currently, no data Available
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Apr 25, 2024 which is today.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Feb 08, 2024. The company reported $0.5 earnings per share for the quarter, beating the consensus estimate of $0.431 by $0.069.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is $0.27.
How many shares outstanding does Dexcom have?
Currently, no data Available
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.5 in its last earnings report, beating expectations of $0.431. Following the earnings report the stock price went down -5.179%.
Which hedge fund is a major shareholder of Dexcom?
Among the largest hedge funds holding Dexcom’s share is Sands Capital Management LLC. It holds Dexcom’s shares valued at 2B.
---
Dexcom Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$154.29 (11.91% Upside)
$154.29 (11.91% Upside)
Blogger Sentiment
Bullish
DXCM Sentiment 86%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 5.3%
Last 30 Days ▼ 5.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.30%
12-Months-Change
Fundamentals
Return on Equity
25.78%
Trailing 12-Months
Asset Growth
16.19%
Trailing 12-Months
Company Description
Dexcom
California-based DexCom, Inc. is a medical device manufacturing company. The company designs, develops and focuses on commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes. Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share.
---
DXCM Company Deck
---
DXCM Earnings Call
Q4 2024
0:00 / 0:00
---
DXCM Revenue Breakdown
72.48% U.S.
27.52% Outside of the U.S.
---
DXCM Stock 12 Months Forecast
Average Price Target
$154.29
▲(11.91% Upside)
Technical Analysis
Best Analysts Covering DXCM
1 Year
1 Year Success Rate
17/19 ratings generated profit
1 Year Average Return
+40.32%
reiterated a buy rating 7 months ago
Copying Mathew Blackman's trades and holding each position for 1 Year would result in 89.47% of your transactions generating a profit, with an average return of +40.32% per trade.
---